hMG-HP en comparación con rFSH en combinaciones de ciclos de ICSI y FIV en fresco y con congelación, en protocolos con agonistas y antagonistas, en clínicas públicas de España: una evaluación económica

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study

“…Economic studies for rFSH have been published in Spain ( Balasch and Barri, 2001 , Barri et al, 2002 , Bosch and Pellicer, 2005 , Hernandez Torres et al, 2015 , Lorente et al, 2013 , Romeu et al, 2003 , Ruiz-Balda et al, 2005 , Slof, 2010 , Wex-Wechowski, 2011 ). On the whole, these studies looked at younger populations than the present study, and therefore the mean dose of rFSH required (IU) was lower.…”

“…The CMA assessed both the daily dose of 300 IU rFSH (base case) and other doses (range 200–375 IU in the sensitivity analysis) to try to reflect the existing variability in current clinical practice where the dose of rFSH is adapted depending on the response of the ovaries ( Balasch and Barri, 2001 , Lorente et al, 2013 , Melo et al, 2010 , Slof, 2010 , Wex-Wechowski, 2011 ). According to clinical experts and the published literature ( Slof, 2010 ), these doses are most commonly used in women of advanced maternal age (mean age 38 years).…”

“…Studies published in Spain on rFSH and uFSH found greater cost efficiency for pregnancies with rFSH because, despite costing more to purchase, fewer cycles were needed to achieve pregnancy and, consequently, the dose required and associated cost were lower ( Balasch and Barri, 2001 , Barri et al, 2002 ; Romeu et al, 2003 ). In turn, the majority of economic evaluations between rFSH and HP-HMG published in Spain indicated that HP-HMG was the most efficient ( Bosch and Pellicer, 2005 , Melo et al, 2010 , Ruiz-Balda et al, 2005 , Wex-Wechowski, 2011 ). In women with a mean age of 38 years, another commonly used protocol is 225 FSH + 75 HP-HMG.…”